Discovering Tomorrow’s Medicines Today

Dr. Sophie Venet (pictured) closely examines the telltale tracks of a culture sample in a petri dish. Welcome to Novimmune! A Swiss biotech company focused
on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.
Promo01

Breakthrough Targeted Medicines

Explore our pipeline of novel antibodies to treat inflammatory and immune-related diseases, cancer, and orphan indications.

Promo02

World-Class Talent and Experience

Meet some of the people
who have made our scientific research and clinical develop-ment advances possible.

Promo03

Cutting-Edge Technology Platforms

Peek inside our proprietary technology plaforms which are used to generate monoclonal and bispecific antibodies.

Promo04

Helping Patients
Heal Themselves

Discover how the human immune system works and how antibody drug therapy can help restore patient health.

NEWS: Novimmune Raises another CHF30 Million (USD 31 Million) from Existing Shareholders
Novimmune announced today it has successfully completed another CHF 30 million (USD 31 million) funding round with existing shareholders.
(10 MAY 2016)

NEWS: Novimmune’s NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH)
Novimmune announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NI-0501 for the treatment of patients with primary HLH with refractory disease, or with recurrent or progressive disease during conventional therapy
(16 MARCH 2016)

NEWS: Novimmune Completes CHF30 Million ($29.8 Million) Funding Round with Existing Shareholders
Novimmune announced today that it has completed a CHF30 million ($29.8 million) funding round.
(11 JAN 2016)

NEWS: Change of Leadership at Novimmune S.A.
Novimmune announced today that the Board of Directors at its meeting of December 16, 2015 appointed Ed Holdener as Chief Executive Officer of the Company, effective immediately.
(21 DEC 2015)

NEWS: Novimmune Abstract Selected for the “Best of ASH” at the 2015 Annual Meeting of the American Society of Hematology (ASH)
Novimmune announced today that the data from the abstract on Hemophagocytic Lymphohistiocytosis (HLH) were presented by Akiko Shimamura, MD, PhD from Boston Children's Hospital, Boston, MA, at the “Best of ASH” at the end of the 2015 Annual Meeting of the American Society of Hematology in Orlando, Florida on Tuesday, December 8.
(15 DEC 2015)

NEWS: Novimmune’s Experimental Drug Selected for Oral Presentation at 2015 Annual Meeting of the American Society of Hematology (ASH)
Novimmune announced today that the abstract on Hemophagocytic Lymphohistiocytosis (HLH) will be presented in the Late-Breaking Abstracts oral session at the 2015 Annual Meeting of the American Society of Hematology in Orlando, Florida on Tuesday, December 8.
(1 DEC 2015)

NEWS: Novimmune’s New Rheumatoid Arthritis Drug Clears Regulatory Hurdles
Novimmune announced today that it received approvals from the U.S. Food and Drug Administration and the U.K. Medicines and Healthcare products Regulatory Agency to begin testing a new experimental drug in patients with rheumatoid arthritis, or RA.
(2 NOV 2015)

NEWS: Novimmune Announces Presentations at 2015 American College of Rheumatology (ACR) Annual Meeting
Novimmune announced plans for several presentations at the upcoming 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, California on November 6-11.
(2 NOV 2015)

NEWS: Novimmune again sponsors Matthew and Andrew Akin Foundation '700 Miles to Hope' bicycle ride in the U.S.
Novimmune announced that it is a $150,000 Matching Sponsor of the 5th annual Matthew and Andrew Akin Foundation “700 Miles to Hope” bicycle ride, an event the company also sponsored last year.
(14 SEP 2015)

NEWS: Novimmune and Baxalta ink international bispecific antibody collaboration
Novimmune SA announced today that it has signed an international research collaboration agreement with Baxalta Incorporated to develop novel bispecific antibodies for an unspecified indication.
(2 SEP 2015)

NEWS: Over 500 race to raise awareness, funds for traumatic disease: '5K to Fight Histio'
More than 400 runners in New York City were joined by an additional 100 virtual participants in several countries to raise awareness of hemophagocytic lymphohistiocytosis, or HLH. Novimmune was a sponsor of this year's 5K event.
(27 JUL 2015)